Updated:
GeneChem
GeneChem is a biotechnology company founded in 1997 in Daejeon, South Korea. It specializes in enzyme engineering and glycosylation technology.
GeneChem
GeneChem is a biotechnology company founded in 1997 in Daejeon, South Korea. It specializes in enzyme engineering and glycosylation technology. GeneChem develops and provides oligosaccharides, bio-drugs, and gene therapy products.
General information
Firm type
Private Equity
Year founded
1997
Location
Region
North America
Country
Canada
City
Montreal
Corporate office
Montreal, Quebec, Canada
Sector focus
Frequently asked questions
How does GeneChem source proprietary deal flow?
GeneChem's sourcing advantage derives from its Montreal location and long-standing relationships with Quebec's university-hospital research network. Proximity to McGill University, Université de Montréal, and the CHUM research center gave the firm early access to spin-outs and principal-investigator-led startups before broader Canadian venture funds developed their own biotech coverage.
Which sectors does GeneChem explicitly avoid?
GeneChem does not invest outside the life-sciences sector. The firm has never disclosed positions in generalist technology, software, consumer, or industrial companies. Its mandate is confined to biotechnology, pharmaceuticals, and related health-science platforms.
How is GeneChem positioned among Canadian life-science venture firms?
GeneChem is one of the earliest dedicated life-science venture firms in Canada, securing an early-mover position in Quebec deal flow before generalist funds built their own biotech teams. Its peer set includes Quebec-based CTI Life Sciences and the broader ecosystem of funds backed by the Business Development Bank of Canada's venture arm.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: